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ANNOUNCEMENT 
The 44th Annual Symposium on the Biology of Skin, entitled "Skin Cancer: Pathomechanisms. 
Epidemiology and Clinical Manifestations, and New Approaches to Therapy," will be held July 
11-15, 1995 at Snowmass Village, Colorado. 
This meeting will provide a comprehensive review of the cellular and molecular biology of 
carcinogenesis, the biology of skin cancers, and modern approaches to treatment. 
Formal presentations by invited speakers, invited poster presentations, and free poster presentations 
will be included. 
Abstracts for the free poster session should be submitted by May 15, 1995 on SID or ESDR abstract 
forms to: 
David A. Norris, M.D. 
44th Annual Symposium on the Biology of Skin 
Box B 144 Department of Dermatology 
University of Colorado School of Medicine 
4200 East Ninth Avenue 
Denver CO 80262. 
